NCT05056779 - Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable | Biotech Hunter

Timeline

Start Date

January 31, 2023

Primary Completion Date

July 31, 2023

Study Completion Date

July 31, 2023

Conditions

Moderate-to-severe Atopic Dermatitis

Interventions

DRUG

Nemolizumab

Participants will receive loading dose of 60 milligram (2×30 mg) subcutaneous (SC) injection of nemolizumab at baseline. Thereafter 30 mg nemolizumab will be administered via single SC injection once in 4 week (Q4W) up to week 12.

DRUG

CD14152 placebo

Participants will receive loading dose of 60 mg (2×30 mg) SC injection of placebo at baseline. Thereafter 30 mg placebo will be administered via single SC injection Q4W up to week 12.